Moderna to Pay US$950 Million to Settle COVID-19 Vaccine Patent Dispute
Source: Investing News Network
2026-03-05 10:52:29 ET
Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine.
The pharmaceuticals giant announced it has reached a global settlement with Arbutus Biopharma (NASDAQ:ABUS) and Genevant Sciences GmbH over claims that Moderna’s vaccines infringed patents related to lipid nanoparticle (LNP) delivery technology.
For further details see:
Moderna to Pay US$950 Million to Settle COVID-19 Vaccine Patent Dispute
BioNTech SE
NASDAQ: BNTX
BNTX Trading
-0.4% G/L:
$100.405 Last:
221,524 Volume:
$100.46 Open:
BNTX Latest News
February 25, 2026 09:00:00 am
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
February 24, 2026 06:45:00 am
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
January 28, 2026 09:15:00 am
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
BNTX Stock Data
$26,377,590,776
95,508,380
N/A
104
N/A
Biotechnology & Life Sciences
Healthcare
DE
Mainz
